BioSyent (CVE:RX) Stock Passes Below Fifty Day Moving Average – What’s Next?

BioSyent Inc. (CVE:RX)’s stock price crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of C$10.98 and traded as low as C$10.98. BioSyent shares last traded at C$11.15, with a volume of 1,201 shares traded.

BioSyent Stock Performance

The company has a 50-day moving average of C$10.98 and a 200-day moving average of C$10.13. The company has a market cap of C$129.23 million, a PE ratio of 18.58 and a beta of 0.93. The company has a quick ratio of 6.91, a current ratio of 6.13 and a debt-to-equity ratio of 3.19.

BioSyent (CVE:RX) last issued its quarterly earnings results on Monday, August 26th. The company reported C$0.13 EPS for the quarter, meeting analysts’ consensus estimates of C$0.13. BioSyent had a return on equity of 20.88% and a net margin of 21.14%. The company had revenue of C$8.95 million during the quarter, compared to the consensus estimate of C$8.80 million. As a group, analysts anticipate that BioSyent Inc. will post 0.6944444 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Seyed Ahmad Ashrafi sold 2,320 shares of the company’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of C$10.95, for a total transaction of C$25,404.00. 33.65% of the stock is currently owned by insiders.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.